RS59710B1 - Metod određivanja mutacionog statusa pik3ca u uzorku - Google Patents
Metod određivanja mutacionog statusa pik3ca u uzorkuInfo
- Publication number
- RS59710B1 RS59710B1 RS20191668A RSP20191668A RS59710B1 RS 59710 B1 RS59710 B1 RS 59710B1 RS 20191668 A RS20191668 A RS 20191668A RS P20191668 A RSP20191668 A RS P20191668A RS 59710 B1 RS59710 B1 RS 59710B1
- Authority
- RS
- Serbia
- Prior art keywords
- sequence
- dna
- seq
- pik3ca
- mutant allele
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/186—Modifications characterised by incorporating a non-extendable or blocking moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/107—Temperature of melting, i.e. Tm
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034231P | 2014-08-07 | 2014-08-07 | |
| PCT/GR2015/000036 WO2016020710A1 (en) | 2014-08-07 | 2015-07-28 | Method of determining pik3ca mutational status in a sample |
| EP15753745.7A EP3198026B1 (en) | 2014-08-07 | 2015-07-28 | Method of determining pik3ca mutational status in a sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59710B1 true RS59710B1 (sr) | 2020-01-31 |
Family
ID=53938365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20191668A RS59710B1 (sr) | 2014-08-07 | 2015-07-28 | Metod određivanja mutacionog statusa pik3ca u uzorku |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11279979B2 (show.php) |
| EP (1) | EP3198026B1 (show.php) |
| JP (1) | JP6770957B2 (show.php) |
| CN (1) | CN106715723B (show.php) |
| CA (1) | CA2957396C (show.php) |
| CY (1) | CY1122647T1 (show.php) |
| DK (1) | DK3198026T3 (show.php) |
| ES (1) | ES2764423T3 (show.php) |
| HR (1) | HRP20192353T1 (show.php) |
| HU (1) | HUE047958T2 (show.php) |
| IL (1) | IL250392B (show.php) |
| LT (1) | LT3198026T (show.php) |
| PL (1) | PL3198026T3 (show.php) |
| PT (1) | PT3198026T (show.php) |
| RS (1) | RS59710B1 (show.php) |
| SI (1) | SI3198026T1 (show.php) |
| SM (1) | SMT202000005T1 (show.php) |
| WO (1) | WO2016020710A1 (show.php) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9115402B2 (en) | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
| US11051814B2 (en) | 2013-09-16 | 2021-07-06 | Oregon Health & Science University | Bioabsorbable clips and applicator for tissue closure |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| CA2965986C (en) | 2014-11-03 | 2019-05-07 | Oregon Health & Science University | Clips and applicator for tissue closure |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| ES3049406T3 (en) | 2014-12-19 | 2025-12-16 | Broad Inst Inc | Methods for profiling the t-cell-receptor repertoire |
| CR20230191A (es) | 2015-05-20 | 2023-07-06 | Dana Farber Cancer Inst Inc | NEOANTIGENOS COMPARTIDOS (Div. exp 2017-584) |
| US10870891B2 (en) | 2017-01-05 | 2020-12-22 | Biodesix, Inc. | Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| CN107287309A (zh) * | 2017-07-06 | 2017-10-24 | 罗保君 | 一种血液循环肿瘤dna点突变检测方法 |
| CN110869516A (zh) * | 2017-07-26 | 2020-03-06 | 积水医疗株式会社 | 检测突变基因的方法 |
| CN109295175A (zh) * | 2017-09-08 | 2019-02-01 | 广州健天基因技术有限公司 | 用于检测人胃肠道间质瘤c-kit基因v559a突变的引物、检测方法及试剂盒 |
| CN109306374A (zh) * | 2017-09-08 | 2019-02-05 | 广州健天基因技术有限公司 | 用于检测人类pik3ca基因e545k突变的引物、检测方法及试剂盒 |
| JP7306618B2 (ja) * | 2017-09-26 | 2023-07-11 | 東ソー株式会社 | がんの転移形成能に関与する因子および前記因子を用いたがん患者の予後予測方法 |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN107937490A (zh) * | 2018-01-15 | 2018-04-20 | 福建农林大学 | 一种非对称pcr的试纸条检测植物病原菌的方法及试剂盒 |
| WO2019155050A1 (en) * | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Method of predicting response to therapy by assessing tumor genetic heterogeneity |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| CN109666747A (zh) * | 2019-02-20 | 2019-04-23 | 天津脉络医学检验有限公司 | 一种引物探针组合物及其应用 |
| US11812966B2 (en) | 2020-04-24 | 2023-11-14 | NeuraMedica Inc. | Clips, appliers, and cartridges |
| KR20230006852A (ko) * | 2020-05-01 | 2023-01-11 | 윌리엄 마쉬 라이스 유니버시티 | 무보정 및 다중 변이체 대립유전자 빈도 정량화를 위한 정량적 블로커 변위 증폭(qbda) 시퀀싱 |
| CN113930500B (zh) * | 2020-07-13 | 2024-11-19 | 铭炽生物科技(上海)有限公司 | 人pik3ca基因突变的数字pcr检测方法及应用 |
| CN112951325B (zh) * | 2021-02-18 | 2023-04-21 | 北京吉因加医学检验实验室有限公司 | 一种用于癌症检测的探针组合的设计方法及其应用 |
| CN113063835B (zh) * | 2021-03-19 | 2022-08-02 | 中山大学 | 一种基于元素标记-电感耦合等离子体质谱检测策略的cfDNA分析方法及其应用 |
| US20250092445A1 (en) * | 2021-08-25 | 2025-03-20 | Manjing Genscript Biotech Co., Ltd. | Primer set and gene chip method for detecting single base mutation |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045690T2 (hu) | 2004-03-02 | 2020-01-28 | Univ Johns Hopkins | A PIK3CA gén mutációi humán rákokban |
| EP2129791A4 (en) * | 2007-02-26 | 2010-07-28 | Wayne John Cancer Inst | BENEFITS OF THE B-RAF DNA MUTATION FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
| US8071338B2 (en) * | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
| CN101445832B (zh) | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| CN102234685B (zh) * | 2010-04-23 | 2014-08-27 | 益善生物技术股份有限公司 | 一种pik3ca基因突变检测液相芯片 |
| EP2646576B1 (en) | 2010-12-03 | 2015-10-28 | Brandeis University | Methods and kits for detecting nucleic acid mutants in wild-type populations |
| CN102533958A (zh) | 2010-12-28 | 2012-07-04 | 苏州科贝生物技术有限公司 | 一种检测人pik3ca基因突变的方法和试剂盒 |
| EP2663652B1 (en) | 2011-01-11 | 2018-11-14 | Roche Diagniostics GmbH | High resolution melting analysis as a prescreening tool |
| WO2012131092A2 (en) * | 2011-03-31 | 2012-10-04 | Signature Diagnostics Ag | Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages |
| EP3382039B1 (en) * | 2011-05-04 | 2023-09-13 | Biocept, Inc. | Methods for detecting nucleic acid sequence variants |
| CN103906848B (zh) * | 2011-08-18 | 2016-03-02 | 雀巢产品技术援助有限公司 | 用于检测等位变体的组合物和方法 |
| JP2013081450A (ja) | 2011-09-27 | 2013-05-09 | Arkray Inc | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット |
| US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| EP2711432A1 (en) | 2012-09-21 | 2014-03-26 | Genomica S.A.U. | Method for detection of BRAF and PI3K mutations |
| EP3666903B1 (en) * | 2013-08-12 | 2025-12-31 | Bio-Rad Laboratories, Inc. | AMPLIFICATION REPORTER GENE CONTAINING OLIGOMERS WITH BASIC PAIRINGS |
-
2015
- 2015-07-28 JP JP2017526770A patent/JP6770957B2/ja active Active
- 2015-07-28 DK DK15753745.7T patent/DK3198026T3/da active
- 2015-07-28 PT PT157537457T patent/PT3198026T/pt unknown
- 2015-07-28 US US15/501,457 patent/US11279979B2/en active Active
- 2015-07-28 PL PL15753745T patent/PL3198026T3/pl unknown
- 2015-07-28 ES ES15753745T patent/ES2764423T3/es active Active
- 2015-07-28 HR HRP20192353TT patent/HRP20192353T1/hr unknown
- 2015-07-28 HU HUE15753745A patent/HUE047958T2/hu unknown
- 2015-07-28 RS RS20191668A patent/RS59710B1/sr unknown
- 2015-07-28 SI SI201531052T patent/SI3198026T1/sl unknown
- 2015-07-28 CN CN201580052321.9A patent/CN106715723B/zh active Active
- 2015-07-28 CA CA2957396A patent/CA2957396C/en active Active
- 2015-07-28 SM SM20200005T patent/SMT202000005T1/it unknown
- 2015-07-28 LT LTEP15753745.7T patent/LT3198026T/lt unknown
- 2015-07-28 WO PCT/GR2015/000036 patent/WO2016020710A1/en not_active Ceased
- 2015-07-28 EP EP15753745.7A patent/EP3198026B1/en active Active
-
2017
- 2017-02-01 IL IL250392A patent/IL250392B/en active IP Right Grant
-
2019
- 2019-12-30 CY CY20191101363T patent/CY1122647T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2957396A1 (en) | 2016-02-11 |
| EP3198026B1 (en) | 2019-10-09 |
| CN106715723A (zh) | 2017-05-24 |
| PL3198026T3 (pl) | 2020-05-18 |
| SMT202000005T1 (it) | 2020-03-13 |
| US11279979B2 (en) | 2022-03-22 |
| HRP20192353T1 (hr) | 2020-03-20 |
| IL250392B (en) | 2020-03-31 |
| ES2764423T3 (es) | 2020-06-03 |
| JP2017523810A (ja) | 2017-08-24 |
| WO2016020710A1 (en) | 2016-02-11 |
| CN106715723B (zh) | 2021-03-30 |
| IL250392A0 (en) | 2017-03-30 |
| DK3198026T3 (da) | 2020-01-20 |
| SI3198026T1 (sl) | 2020-02-28 |
| PT3198026T (pt) | 2020-01-16 |
| JP6770957B2 (ja) | 2020-10-21 |
| EP3198026A1 (en) | 2017-08-02 |
| HUE047958T2 (hu) | 2020-05-28 |
| CY1122647T1 (el) | 2021-03-12 |
| US20170233821A1 (en) | 2017-08-17 |
| LT3198026T (lt) | 2020-01-27 |
| CA2957396C (en) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3198026B1 (en) | Method of determining pik3ca mutational status in a sample | |
| US12270081B2 (en) | Method for quantification of PD-L1 expression | |
| AU2022228167B2 (en) | Methods and materials for assessing loss of heterozygosity | |
| Voutsina et al. | Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer | |
| JP2012501652A (ja) | 悪性神経膠腫におけるイソクエン酸デヒドロゲナーゼ遺伝子および他の遺伝子の遺伝子変化 | |
| Beddowes et al. | Predicting treatment resistance and relapse through circulating DNA | |
| CA3198134A1 (en) | Immunotherapy response signature | |
| WO2012131092A2 (en) | Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages | |
| US12391985B2 (en) | Method of determining PIK3CA mutational status in a sample | |
| EP2783015A1 (en) | Responsiveness to angiogenesis inhibitors | |
| Palande et al. | A liquid biopsy platform for detecting gene-gene fusions as glioma diagnostic biomarkers and drug targets | |
| US20250129428A1 (en) | Methods and materials for predicting the progression of prostate cancer and treating same | |
| HK1241934A1 (en) | Method of determining pik3ca mutational status in a sample | |
| HK1241934B (en) | Method of determining pik3ca mutational status in a sample | |
| Indriastuti et al. | Biomarkers of Breast Cancer | |
| Anandappa | Developing biomarker guided treatments for colorectal cancer | |
| Richter-Pechańska | A novel approach to develop predictive biomarkers: prediction of response to anti-EGFR therapy in a large panel of patient-derived colorectal cancer xenograft models | |
| Pechanska | A novel approach to develop predictive biomarkers | |
| HK1197755A (en) | Responsiveness to angiogenesis inhibitors |